INTRODUCTION
Calciphylaxis is an extreme and potentially fatal complication of secondary hyperparathyroidism (SHPT) whose incidence is assessed between 1 to 4% of patients suffering from End Stage Renal Disease (ESRD). It is characterized by calcification of tunica media of skin arteries, subcutaneous fat tissues, visceral organs and muscles. These histological features are associated to a clinical picture characterized by cutaneous and subcutaneous manifestations and by the presence of violaceous nodular lesions of the skin that can evolve into tissue necrosis, ulcers that do not heal, and cutaneous gangrene (Fig. 1) . In advanced stage these lesions may be found in internal organs such as heart and lung 1 and consequent clinical symptoms.
The death rate for calciphylaxis is about 60-80% and depends not exclusively on organ involved in the pathological process but also on the extension of necrotic cutaneous lesions, possible sites of bacterial contamination that can lead to sepsis.
The extreme variability of symptoms is not clear yet and it does not seem related to serum parathormone (PTH) levels. It is probably due to calcium-phosphate ratio and individual variables not fully understood such as sensitization to PTH receptor, vitamin D levels and hypocalcaemia. For the above reasons, it is often very difficult to formulate a defined prognosis. Possible therapies that can modify the course of the disease are surgical parathyroidectomy [2] [3] [4] which should be performed as soon as possible in order to restore physiological PTH levels-the administration of drugs for normalizing calcium-phospho- rus balance, as sevelamer (a phosphorus binding drug) and Cinacalcet (that acts as a calcimimetic activating the calcium-sensing receptors thus reducing PTH secretion 5 ), and technical stratagems such as reducing calcium levels in dialysis buffers.
It is reported that intravenous administration of sodium thiosulfate 6, 7 before surgical parathyroidectomy increases the solubility of calcium deposits, reduces disseminated precipitation of calcium crystals and counteracts occlusions in small and medium calibre arteries, improving clinical picture acting as antioxidant and calcium binding drug.
CASE REPORT
We report the case of a 60 year old female patient suffering from ERSD, on haemodialysis treatment from 2001 subsequent to haemolytic uremic syndrome (HUS), and who underwent a kidney transplant from a deceased donor on April 2008. Shortly after renal transplant, the relapse of HUS (accompanying with worsening of the graft) required plasma-aphaeresis, blood transfusions, and haemodialysis. The problem was resolved and graft function was resumed up to December 2008 followed by loss of the graft when the patient was returned to dialysis treatment. On April 2010 the patient came to our attention again for the onset of a severe clinical picture of skin lesions, (Fig. 2) . For this reason we started a diagnostic workup monitoring calcium-phosphate metabolism and performing a parathyroid ultrasonography and technetium-99m-sestamibi scintigraphy that confirmed SHPT, with a PTH level of 1025 pg/ml (normal range 10-65 pg/ml).
Parathyroidectomy (Fig. 3) , performed using a intraoperative dosage of PTH (Future Diagnostic STAT-IO-I-PTH Kit, US), removed the glands leading to a reduction of PTH levels of more than 88%, Table1 shows the main clinical data regarding bone metabolism before and after intervention. Histological analysis confirmed that all the five glands removed showed signs of hyperplasia 9, 10 . Unfortunately, after surgical intervention, the clinical picture did not improve thus it was decided to initiate therapy based on sodium thiosulphate at dosage of 25 grams three times a week after dialysis treatment.
The treatment with sodium thiosulphate improved the skin lesions but was ineffective in terms of the general clinical status, which, instead, worsened because of the appearance of septic complications that, although treated with aggressive broad-spectrum antibiotics, caused the death of the patient.
DISCUSSION
HUS and SHPT have both small and medium calibre arteries as targets: their coexistence is considered a negative prognostic factor particularly when the SHPT is associated to myelofibrosis 11 . The role of metastatic calcium deposits in vessels, causing a complex hypersensibility reaction, plays probably the main role in progression of the disease particularly when associated with the onset of a thrombotic micro-angiopathy related to HUS. In such a clinical picture the administration of sodium thiosulphate is insufficient to counteract the deleterious effect of ectopic precipitation of calcium crystals.
CONCLUSIONS
Calciphylaxis has a high mortality rate. Its pathogenesis is still not clear because only few patients suffering from SHPT develop such a complication and, further, there is no correlation between clinical picture and lab tests such as those evaluating calcium-phosphate ratio. Probably a main role is played by underestimated preexisting vascular alterations that lead to calcium deposits. Published data show that the presence of supernumerary glands is associated to pathologies causing thrombotic lesions; in the light of the above considerations, we believe that HUS should be considered a negative prognostic factor. Moreover, the appearance of skin lesions on the proximal side of the upper and lower limbs is related to a higher mortality rate 12 . We conclude that, in absence of tools for risk stratification for these patients, the therapy of choice is a preventive parathyroidectomy before the appearance of advanced lesions.
